{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal&page=19", "query": { "condition": "Renal", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 6437, "total_pages": 644, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T17:40:23.312Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00550654", "title": "Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)", "Metastatic Cancer", "Ovarian Cancer", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "questionnaire administration", "type": "OTHER" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "hypofractionated radiation therapy", "type": "RADIATION" }, { "name": "image-guided radiation therapy", "type": "RADIATION" }, { "name": "tomotherapy", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2007-10", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550654" }, { "nct_id": "NCT00090753", "title": "A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Methoxy Polyethylene Glycol-Epoetin Beta", "type": "DRUG" }, { "name": "Epoetin alfa", "type": "DRUG" }, { "name": "Epoetin beta", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1228, "start_date": "2004-10", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2012-02-14", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090753" }, { "nct_id": "NCT06576661", "title": "Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Behavior and Post-operative Outcomes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Stone", "Nephrolithiasis" ], "interventions": [ { "name": "INTRARENAL PRESSURE MONITORING VISIBLE", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-01-28", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06576661" }, { "nct_id": "NCT05003986", "title": "Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Segmental Glomerulosclerosis", "Minimal Change Disease", "Immunoglobulin A Nephropathy", "IgA Vasculitis", "Alport Syndrome" ], "interventions": [ { "name": "Sparsentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Travere Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 67, "start_date": "2021-08-12", "completion_date": "2027-04-12", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 23, "location_summary": "Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05003986" }, { "nct_id": "NCT06712654", "title": "A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperphosphatemia", "Chronic Kidney Disease Requiring Chronic Dialysis", "End Stage Renal Disease on Dialysis" ], "interventions": [ { "name": "AP306 75 mg BID", "type": "DRUG" }, { "name": "AP306 125 mg BID", "type": "DRUG" }, { "name": "AP306 150 mg BID", "type": "DRUG" }, { "name": "AP306 75 mg TID", "type": "DRUG" }, { "name": "AP306 100 mg TID", "type": "DRUG" }, { "name": "AP306 125 mg TID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R1 Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2026-06-01", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 24, "location_summary": "Huntsville, Alabama • Chula Vista, California • Los Angeles, California + 19 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Dimas", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712654" }, { "nct_id": "NCT03149159", "title": "Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Steriotactic radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-04-01", "completion_date": "2018-04-01", "has_results": false, "last_update_posted_date": "2018-06-18", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03149159" }, { "nct_id": "NCT01030354", "title": "Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Weight Reduction", "Obesity", "Weight Management" ], "interventions": [ { "name": "Herbalife Meal Replacements", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 100, "start_date": "2004-07", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030354" }, { "nct_id": "NCT00003091", "title": "High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hoag Memorial Hospital Presbyterian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1996-01", "completion_date": "2000-01", "has_results": false, "last_update_posted_date": "2011-05-12", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 4, "location_summary": "Newport Beach, California • Bloomington, Indiana • Knoxville, Tennessee + 1 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "Bryan", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003091" }, { "nct_id": "NCT04258397", "title": "Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "Pirfenidone", "type": "DRUG" }, { "name": "matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veterans Medical Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 200, "start_date": "2020-10-26", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 2, "location_summary": "San Diego, California • San Francisco, California", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04258397" }, { "nct_id": "NCT04531280", "title": "Rural Home Hospital: Proof of Concept", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infection", "Heart Failure", "Chronic Obstructive Pulmonary Disease", "Asthma", "Gout Flare", "Chronic Kidney Diseases", "Hypertensive Urgency", "Atrial Fibrillation Rapid", "Anticoagulants; Increased" ], "interventions": [ { "name": "Home hospital care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-02-18", "completion_date": "2021-05-07", "has_results": true, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-10-23T17:40:23.312Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04531280" } ] }